Biosimilars in Oncology: Addressing Awareness

Business Practice

View More Business Development Legal Policy Practice Regulatory

Business Development Legal Policy Practice Regulatory

All Videos Insights Interviews Peer Exchange Podcasts

Gastroenterology

Dermatology Endocrinology Gastroenterology Legal Neurology Oncology Ophthalmology Rare Disease Rheumatology

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Biosimilar Resources

Authors Biosimilar Resources Polls

About
Contact
Advisory Board
Do Not Sell My Information
Terms & Conditions
Privacy Policy

© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.

Business PracticeSee All >

Business
Development
Legal
Policy
Practice
Regulatory

About
Contact
Advisory Board
Do Not Sell My Information
Terms & Conditions
Privacy Policy

© 2021 MJH Life Sciences^™ and Center for Biosimilars®. All rights reserved.

May 29, 2020

Related Content:

Peer ExchangeOncology

News Briefs: Samsung Bioepis, Cipla, Biocon Report Progress

News Briefs: Samsung Bioepis, Cipla, Biocon Report Progress

Opinion: A Short History of Biosimilars

Opinion: A Short History of Biosimilars

Study: Trastuzumab Biosimilar IV Offers Better Value than Reference SC

Study: Trastuzumab Biosimilar IV Offers Better Value than Reference SC